FGFR3 and neoplasm: In addition, we defined distinct tumour-immune phenotypes and correlated our findings with previous data on PD-L1 expression and FGFR3 mutation status, PIK3CA mutation status, ARID1A, Nectin-4 and Trop-2 expression, to investigate the potential role of immune cells as biomarkers for ICI and targeted therapy.